Overuse of acute migraine medications and migraine chronification

Marcelo E. Bigal, Richard B. Lipton

Research output: Contribution to journalArticle

75 Citations (Scopus)

Abstract

Among individuals with episodic migraine, the influence of excessive acute medication use on the development of chronic migraine depends upon within-person characteristics (eg, headache frequency), class of drug, and frequency of medication use. Available data suggest that opioids induce migraine chronification (progression), and the effect is dose dependent (critical dose around 8 days of exposure per month) and more pronounced in men. Barbiturates also induce migraine progression, and the effect is dose dependent (critical dose around 5 days of exposure per month) and more pronounced in women. Triptans induce migraine progression only in those with high migraine frequency at baseline (10-14 days per month), but not overall. NSAIDs protect against migraine progression unless individuals have 10 or more headache days per month (when they become inducers, rather than protective). Finally, caffeine-containing over-the-counter products increase risk of progression. While we await randomized trials, these findings should inform the choice of acute migraine treatments with the goal of reducing the risk of migraine progression to chronic migraine.

Original languageEnglish (US)
Pages (from-to)301-307
Number of pages7
JournalCurrent Pain and Headache Reports
Volume13
Issue number4
DOIs
StatePublished - 2009
Externally publishedYes

Fingerprint

Migraine Disorders
Headache
Tryptamines
Barbiturates
Non-Steroidal Anti-Inflammatory Agents
Caffeine
Opioid Analgesics

ASJC Scopus subject areas

  • Clinical Neurology
  • Anesthesiology and Pain Medicine

Cite this

Overuse of acute migraine medications and migraine chronification. / Bigal, Marcelo E.; Lipton, Richard B.

In: Current Pain and Headache Reports, Vol. 13, No. 4, 2009, p. 301-307.

Research output: Contribution to journalArticle

@article{52ba782e9cd24f47aeeb1fa59f95c5ef,
title = "Overuse of acute migraine medications and migraine chronification",
abstract = "Among individuals with episodic migraine, the influence of excessive acute medication use on the development of chronic migraine depends upon within-person characteristics (eg, headache frequency), class of drug, and frequency of medication use. Available data suggest that opioids induce migraine chronification (progression), and the effect is dose dependent (critical dose around 8 days of exposure per month) and more pronounced in men. Barbiturates also induce migraine progression, and the effect is dose dependent (critical dose around 5 days of exposure per month) and more pronounced in women. Triptans induce migraine progression only in those with high migraine frequency at baseline (10-14 days per month), but not overall. NSAIDs protect against migraine progression unless individuals have 10 or more headache days per month (when they become inducers, rather than protective). Finally, caffeine-containing over-the-counter products increase risk of progression. While we await randomized trials, these findings should inform the choice of acute migraine treatments with the goal of reducing the risk of migraine progression to chronic migraine.",
author = "Bigal, {Marcelo E.} and Lipton, {Richard B.}",
year = "2009",
doi = "10.1007/s11916-009-0048-3",
language = "English (US)",
volume = "13",
pages = "301--307",
journal = "Current Pain and Headache Reports",
issn = "1531-3433",
publisher = "Current Science, Inc.",
number = "4",

}

TY - JOUR

T1 - Overuse of acute migraine medications and migraine chronification

AU - Bigal, Marcelo E.

AU - Lipton, Richard B.

PY - 2009

Y1 - 2009

N2 - Among individuals with episodic migraine, the influence of excessive acute medication use on the development of chronic migraine depends upon within-person characteristics (eg, headache frequency), class of drug, and frequency of medication use. Available data suggest that opioids induce migraine chronification (progression), and the effect is dose dependent (critical dose around 8 days of exposure per month) and more pronounced in men. Barbiturates also induce migraine progression, and the effect is dose dependent (critical dose around 5 days of exposure per month) and more pronounced in women. Triptans induce migraine progression only in those with high migraine frequency at baseline (10-14 days per month), but not overall. NSAIDs protect against migraine progression unless individuals have 10 or more headache days per month (when they become inducers, rather than protective). Finally, caffeine-containing over-the-counter products increase risk of progression. While we await randomized trials, these findings should inform the choice of acute migraine treatments with the goal of reducing the risk of migraine progression to chronic migraine.

AB - Among individuals with episodic migraine, the influence of excessive acute medication use on the development of chronic migraine depends upon within-person characteristics (eg, headache frequency), class of drug, and frequency of medication use. Available data suggest that opioids induce migraine chronification (progression), and the effect is dose dependent (critical dose around 8 days of exposure per month) and more pronounced in men. Barbiturates also induce migraine progression, and the effect is dose dependent (critical dose around 5 days of exposure per month) and more pronounced in women. Triptans induce migraine progression only in those with high migraine frequency at baseline (10-14 days per month), but not overall. NSAIDs protect against migraine progression unless individuals have 10 or more headache days per month (when they become inducers, rather than protective). Finally, caffeine-containing over-the-counter products increase risk of progression. While we await randomized trials, these findings should inform the choice of acute migraine treatments with the goal of reducing the risk of migraine progression to chronic migraine.

UR - http://www.scopus.com/inward/record.url?scp=67651111652&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67651111652&partnerID=8YFLogxK

U2 - 10.1007/s11916-009-0048-3

DO - 10.1007/s11916-009-0048-3

M3 - Article

C2 - 19586594

AN - SCOPUS:67651111652

VL - 13

SP - 301

EP - 307

JO - Current Pain and Headache Reports

JF - Current Pain and Headache Reports

SN - 1531-3433

IS - 4

ER -